"Designing Growth Strategies is in our DNA"

Infectious Disease Point-of-care (POC) Diagnostics Market Size, Share & COVID-19 Impact Analysis, By Technique (Lateral Flow Immunoassay, Agglutination Test and Others), By Disease (HIV, Hepatitis B Virus, Pneumonia/Streptococcus Associated Infections, RSV, Influenza, Clostridium Difficile Infections, Hepatitis C Virus, Methicillin-Resistant Staphylococcus Aureus, Tuberculosis, and Others), By Disease, COVID-19 Point-of-care (POC) Diagnostics, By End User (Hospital Bedside, Physicians Office Lab, Urgent Care & Retail Clinics and Others), and Regional Forecast, 2026-2034

Last Updated: March 16, 2026 | Format: PDF | Report ID: FBI104307

 

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Prevalence of Key Infectious Diseases, By Key Countries, 2025
    2. New Product Launches
    3. Key Industrial Developments (Mergers, Acquisitions, Partnerships, etc.)
    4. Technological Advancements in Infectious Disease Point of Care (POC) Diagnostics
    5. Impact of COVID-19 on Infectious Disease Point of Care (POC) Diagnostics Market
    6. Overview of Initiatives for Infectious Disease Point of Care (POC) Diagnostics in Emerging Countries
    7. Pricing Analysis of Various Infectious Disease Point of Care (POC) Diagnostics, By Key Companies
    8. Analysis of Product Features of Key Infectious Disease Point of Care (POC) Diagnostics, By Key Companies
  5. Global Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Technique
      1. Lateral Flow Immunoassay (LFIA)
      2. Agglutination Tests
      3. Flow-through Tests / Immunoconcentration Assays
      4. Molecular Diagnostics
      5. Others
    2. Market Analysis, Insights and Forecast – By Disease
      1. Human Immunodeficiency Virus (HIV)
      2. Hepatitis B Virus (HBV)
      3. Pneumonia / Streptococcus Associated Infections
      4. Respiratory Syncytial Virus (RSV)
      5. Influenza
      6. Clostridium difficile infection (CDI)
      7. Hepatitis C Virus (HCV)
      8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
      9. Tuberculosis (TB)
      10. COVID-19
      11. Others
    3. Market Analysis, Insights and Forecast – By End User
      1. Hospital Bedside
      2. Physician's Office Lab
      3. Urgent Care & Retail Clinics
      4. Home & Self-Testing
      5. Nursing Homes
      6. Others
    4. Market Analysis, Insights and Forecast – By Geography
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
  6. North America Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Technique
      1. Lateral Flow Immunoassay (LFIA)
      2. Agglutination Tests
      3. Flow-through Tests / Immunoconcentration Assays
      4. Molecular Diagnostics
      5. Others
    2. Market Analysis, Insights and Forecast – By Disease
      1. Human Immunodeficiency Virus (HIV)
      2. Hepatitis B Virus (HBV)
      3. Pneumonia / Streptococcus Associated Infections
      4. Respiratory Syncytial Virus (RSV)
      5. Influenza
      6. Clostridium difficile infection (CDI)
      7. Hepatitis C Virus (HCV)
      8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
      9. Tuberculosis (TB)
      10. COVID-19
      11. Others
    3. Market Analysis, Insights and Forecast – By End User
      1. Hospital Bedside
      2. Physician's Office Lab
      3. Urgent Care & Retail Clinics
      4. Home & Self-Testing
      5. Nursing Homes
      6. Others
    4. Market Analysis, Insights and Forecast – By Country
      1. U.S.
      2. Canada
  7. Europe Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Technique
      1. Lateral Flow Immunoassay (LFIA)
      2. Agglutination Tests
      3. Flow-through Tests / Immunoconcentration Assays
      4. Molecular Diagnostics
      5. Others
    2. Market Analysis, Insights and Forecast – By Disease
      1. Human Immunodeficiency Virus (HIV)
      2. Hepatitis B Virus (HBV)
      3. Pneumonia / Streptococcus Associated Infections
      4. Respiratory Syncytial Virus (RSV)
      5. Influenza
      6. Clostridium difficile infection (CDI)
      7. Hepatitis C Virus (HCV)
      8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
      9. Tuberculosis (TB)
      10. COVID-19
      11. Others
    3. Market Analysis, Insights and Forecast – By End User
      1. Hospital Bedside
      2. Physician's Office Lab
      3. Urgent Care & Retail Clinics
      4. Home & Self-Testing
      5. Nursing Homes
      6. Others
    4. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. U.K.
      2. Germany
      3. France
      4. Spain
      5. Italy
      6. Scandinavia
      7. Rest of Europe
  8. Asia Pacific Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Technique
      1. Lateral Flow Immunoassay (LFIA)
      2. Agglutination Tests
      3. Flow-through Tests / Immunoconcentration Assays
      4. Molecular Diagnostics
      5. Others
    2. Market Analysis, Insights and Forecast – By Disease
      1. Human Immunodeficiency Virus (HIV)
      2. Hepatitis B Virus (HBV)
      3. Pneumonia / Streptococcus Associated Infections
      4. Respiratory Syncytial Virus (RSV)
      5. Influenza
      6. Clostridium difficile infection (CDI)
      7. Hepatitis C Virus (HCV)
      8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
      9. Tuberculosis (TB)
      10. COVID-19
      11. Others
    3. Market Analysis, Insights and Forecast – By End User
      1. Hospital Bedside
      2. Physician's Office Lab
      3. Urgent Care & Retail Clinics
      4. Home & Self-Testing
      5. Nursing Homes
      6. Others
    4. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. Japan
      2. China
      3. India
      4. Australia
      5. Southeast Asia
      6. Rest of Asia Pacific
  9. Latin America Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Technique
      1. Lateral Flow Immunoassay (LFIA)
      2. Agglutination Tests
      3. Flow-through Tests / Immunoconcentration Assays
      4. Molecular Diagnostics
      5. Others
    2. Market Analysis, Insights and Forecast – By Disease
      1. Human Immunodeficiency Virus (HIV)
      2. Hepatitis B Virus (HBV)
      3. Pneumonia / Streptococcus Associated Infections
      4. Respiratory Syncytial Virus (RSV)
      5. Influenza
      6. Clostridium difficile infection (CDI)
      7. Hepatitis C Virus (HCV)
      8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
      9. Tuberculosis (TB)
      10. COVID-19
      11. Others
    3. Market Analysis, Insights and Forecast – By End User
      1. Hospital Bedside
      2. Physician's Office Lab
      3. Urgent Care & Retail Clinics
      4. Home & Self-Testing
      5. Nursing Homes
      6. Others
    4. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. Brazil
      2. Mexico
      3. Rest of Latin America
  10. Middle East & Africa Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Technique
      1. Lateral Flow Immunoassay (LFIA)
      2. Agglutination Tests
      3. Flow-through Tests / Immunoconcentration Assays
      4. Molecular Diagnostics
      5. Others
    2. Market Analysis, Insights and Forecast – By Disease
      1. Human Immunodeficiency Virus (HIV)
      2. Hepatitis B Virus (HBV)
      3. Pneumonia / Streptococcus Associated Infections
      4. Respiratory Syncytial Virus (RSV)
      5. Influenza
      6. Clostridium difficile infection (CDI)
      7. Hepatitis C Virus (HCV)
      8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
      9. Tuberculosis (TB)
      10. COVID-19
      11. Others
    3. Market Analysis, Insights and Forecast – By End User
      1. Hospital Bedside
      2. Physician's Office Lab
      3. Urgent Care & Retail Clinics
      4. Home & Self-Testing
      5. Nursing Homes
      6. Others
    4. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. GCC
      2. South Africa
      3. Rest of Middle East & Africa
  11. Competitive Analysis
    1. Global Market Share Analysis (2025)
    2. Company Profiles
      1. F. Hoffmann-La Roche Ltd
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      2. Thermo Fisher Scientific Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      3. Quest Diagnostics Incorporated
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      4. BD
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      5. bioMérieux SA
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      6. Cardinal Health, Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      7. Cepheid
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      8. Mesa Biotech
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      9. Trinity Biotech
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      10. Quidel Corporation
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      11. Bio-Rad Laboratories, Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      12. Abbott
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      13. Other Prominent Players
  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Prevalence of Key Infectious Diseases, By Key Countries, 2025
    2. New Product Launches
    3. Key Industrial Developments (Mergers, Acquisitions, Partnerships, etc.)
    4. Technological Advancements in Infectious Disease Point of Care (POC) Diagnostics
    5. Impact of COVID-19 on Infectious Disease Point of Care (POC) Diagnostics Market
    6. Overview of Initiatives for Infectious Disease Point of Care (POC) Diagnostics in Emerging Countries
    7. Pricing Analysis of Various Infectious Disease Point of Care (POC) Diagnostics, By Key Companies
    8. Analysis of Product Features of Key Infectious Disease Point of Care (POC) Diagnostics, By Key Companies
  5. Global Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Technique
      1. Lateral Flow Immunoassay (LFIA)
      2. Agglutination Tests
      3. Flow-through Tests / Immunoconcentration Assays
      4. Molecular Diagnostics
      5. Others
    2. Market Analysis, Insights and Forecast – By Disease
      1. Human Immunodeficiency Virus (HIV)
      2. Hepatitis B Virus (HBV)
      3. Pneumonia / Streptococcus Associated Infections
      4. Respiratory Syncytial Virus (RSV)
      5. Influenza
      6. Clostridium difficile infection (CDI)
      7. Hepatitis C Virus (HCV)
      8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
      9. Tuberculosis (TB)
      10. COVID-19
      11. Others
    3. Market Analysis, Insights and Forecast – By End User
      1. Hospital Bedside
      2. Physician's Office Lab
      3. Urgent Care & Retail Clinics
      4. Home & Self-Testing
      5. Nursing Homes
      6. Others
    4. Market Analysis, Insights and Forecast – By Geography
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
  6. North America Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Technique
      1. Lateral Flow Immunoassay (LFIA)
      2. Agglutination Tests
      3. Flow-through Tests / Immunoconcentration Assays
      4. Molecular Diagnostics
      5. Others
    2. Market Analysis, Insights and Forecast – By Disease
      1. Human Immunodeficiency Virus (HIV)
      2. Hepatitis B Virus (HBV)
      3. Pneumonia / Streptococcus Associated Infections
      4. Respiratory Syncytial Virus (RSV)
      5. Influenza
      6. Clostridium difficile infection (CDI)
      7. Hepatitis C Virus (HCV)
      8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
      9. Tuberculosis (TB)
      10. COVID-19
      11. Others
    3. Market Analysis, Insights and Forecast – By End User
      1. Hospital Bedside
      2. Physician's Office Lab
      3. Urgent Care & Retail Clinics
      4. Home & Self-Testing
      5. Nursing Homes
      6. Others
    4. Market Analysis, Insights and Forecast – By Country
      1. U.S.
      2. Canada
  7. Europe Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Technique
      1. Lateral Flow Immunoassay (LFIA)
      2. Agglutination Tests
      3. Flow-through Tests / Immunoconcentration Assays
      4. Molecular Diagnostics
      5. Others
    2. Market Analysis, Insights and Forecast – By Disease
      1. Human Immunodeficiency Virus (HIV)
      2. Hepatitis B Virus (HBV)
      3. Pneumonia / Streptococcus Associated Infections
      4. Respiratory Syncytial Virus (RSV)
      5. Influenza
      6. Clostridium difficile infection (CDI)
      7. Hepatitis C Virus (HCV)
      8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
      9. Tuberculosis (TB)
      10. COVID-19
      11. Others
    3. Market Analysis, Insights and Forecast – By End User
      1. Hospital Bedside
      2. Physician's Office Lab
      3. Urgent Care & Retail Clinics
      4. Home & Self-Testing
      5. Nursing Homes
      6. Others
    4. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. U.K.
      2. Germany
      3. France
      4. Spain
      5. Italy
      6. Scandinavia
      7. Rest of Europe
  8. Asia Pacific Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Technique
      1. Lateral Flow Immunoassay (LFIA)
      2. Agglutination Tests
      3. Flow-through Tests / Immunoconcentration Assays
      4. Molecular Diagnostics
      5. Others
    2. Market Analysis, Insights and Forecast – By Disease
      1. Human Immunodeficiency Virus (HIV)
      2. Hepatitis B Virus (HBV)
      3. Pneumonia / Streptococcus Associated Infections
      4. Respiratory Syncytial Virus (RSV)
      5. Influenza
      6. Clostridium difficile infection (CDI)
      7. Hepatitis C Virus (HCV)
      8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
      9. Tuberculosis (TB)
      10. COVID-19
      11. Others
    3. Market Analysis, Insights and Forecast – By End User
      1. Hospital Bedside
      2. Physician's Office Lab
      3. Urgent Care & Retail Clinics
      4. Home & Self-Testing
      5. Nursing Homes
      6. Others
    4. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. Japan
      2. China
      3. India
      4. Australia
      5. Southeast Asia
      6. Rest of Asia Pacific
  9. Latin America Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Technique
      1. Lateral Flow Immunoassay (LFIA)
      2. Agglutination Tests
      3. Flow-through Tests / Immunoconcentration Assays
      4. Molecular Diagnostics
      5. Others
    2. Market Analysis, Insights and Forecast – By Disease
      1. Human Immunodeficiency Virus (HIV)
      2. Hepatitis B Virus (HBV)
      3. Pneumonia / Streptococcus Associated Infections
      4. Respiratory Syncytial Virus (RSV)
      5. Influenza
      6. Clostridium difficile infection (CDI)
      7. Hepatitis C Virus (HCV)
      8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
      9. Tuberculosis (TB)
      10. COVID-19
      11. Others
    3. Market Analysis, Insights and Forecast – By End User
      1. Hospital Bedside
      2. Physician's Office Lab
      3. Urgent Care & Retail Clinics
      4. Home & Self-Testing
      5. Nursing Homes
      6. Others
    4. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. Brazil
      2. Mexico
      3. Rest of Latin America
  10. Middle East & Africa Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Technique
      1. Lateral Flow Immunoassay (LFIA)
      2. Agglutination Tests
      3. Flow-through Tests / Immunoconcentration Assays
      4. Molecular Diagnostics
      5. Others
    2. Market Analysis, Insights and Forecast – By Disease
      1. Human Immunodeficiency Virus (HIV)
      2. Hepatitis B Virus (HBV)
      3. Pneumonia / Streptococcus Associated Infections
      4. Respiratory Syncytial Virus (RSV)
      5. Influenza
      6. Clostridium difficile infection (CDI)
      7. Hepatitis C Virus (HCV)
      8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
      9. Tuberculosis (TB)
      10. COVID-19
      11. Others
    3. Market Analysis, Insights and Forecast – By End User
      1. Hospital Bedside
      2. Physician's Office Lab
      3. Urgent Care & Retail Clinics
      4. Home & Self-Testing
      5. Nursing Homes
      6. Others
    4. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. GCC
      2. South Africa
      3. Rest of Middle East & Africa
  11. Competitive Analysis
    1. Global Market Share Analysis (2025)
    2. Company Profiles
      1. F. Hoffmann-La Roche Ltd
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      2. Thermo Fisher Scientific Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      3. Quest Diagnostics Incorporated
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      4. BD
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      5. bioMérieux SA
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      6. Cardinal Health, Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      7. Cepheid
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      8. Mesa Biotech
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      9. Trinity Biotech
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      10. Quidel Corporation
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      11. Bio-Rad Laboratories, Inc.
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      12. Abbott
        1. Overview
        2. Products
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      13. Other Prominent Players
Read Less

Figure 01: Global Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), by Region, 2025 & 2034

Figure 02: Global Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Technique, 2025 & 2034

Figure 03: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Lateral Flow Immunoassay (LFIA), 2021-2034

Figure 04: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Agglutination Tests, 2021-2034

Figure 05: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Flow-through Tests / Immunoconcentration Assays, 2021-2034

Figure 06: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Molecular Diagnostics, 2021-2034

Figure 07 Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Others, 2021-2034

Figure 08: Global Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Disease Type, 2025 & 2034

Figure 09: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Human Immunodeficiency Virus (HIV) 2021-2034

Figure 10: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Hepatitis B Virus (HBV) 2021-2034

Figure 11: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Pneumonia / Streptococcus Associated Infections 2021-2034

Figure 12: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Respiratory Syncytial Virus (RSV) 2021-2034

Figure 13: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Influenza 2021-2034

Figure 14: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Clostridium difficile infection (CDI) 2021-2034

Figure 15: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Hepatitis C Virus (HCV) 2021-2034

Figure 16: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Methicillin-Resistant Staphylococcus Aureus (MRSA) 2021-2034

Figure 17: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Tuberculosis (TB) 2021-2034

Figure 18: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By COVID-19 2021-2034

Figure 19: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Others 2021-2034

Figure 20: Global Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By End User, 2025 & 2034

Figure 21: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Hospital Bedside, 2021-2034

Figure 22: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Physician's Office Lab2021-2034

Figure 23: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Urgent Care & Retail Clinics 2021-2034

Figure 24: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Home & Self Testing 2021-2034

Figure 25: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Nursing Homes, 2021-2034

Figure 26: Global Infectious Disease Point of Care (POC) Diagnostics Market Forecast (USD billion), By Others 2021-2034

Figure 27: Global Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Region, 2025 & 2034

Figure 28: North America Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Technique, 2025 & 2034

Figure 29: North America Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Technique, 2025

Figure 30: North America Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Disease Type, 2025 & 2034

Figure 31: North America Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Disease Type, 2025

Figure 32: North America Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By End User, 2025 & 2034

Figure 33: North America Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By End User, 2025

Figure 34: North America Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Country, 2025 & 2034

Figure 35: North America Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Country, 2025

Figure 36: Europe Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Technique, 2025 & 2034

Figure 37: Europe Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Technique, 2025

Figure 38: Europe Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Disease Type, 2025 & 2034

Figure 39: Europe Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Disease Type, 2025

Figure 40: Europe Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By End User, 2025 & 2034

Figure 41: Europe Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By End User, 2025

Figure 42: Europe Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Country/Sub-region, 2025 & 2034

Figure 43: Europe Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Country/Sub-region, 2025

Figure 44: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Technique, 2025 & 2034

Figure 45: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Technique, 2025

Figure 46: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Disease Type, 2025 & 2034

Figure 47: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Disease Type, 2025

Figure 48: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By End User, 2025 & 2034

Figure 49: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By End User, 2025

Figure 50: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Country/Sub-region, 2025 & 2034

Figure 51: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Country/Sub-region, 2025

Figure 52: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Technique, 2025 & 2034

Figure 53: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Technique, 2025

Figure 54: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Disease Type, 2025 & 2034

Figure 55: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Disease Type, 2025

Figure 56: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By End User, 2025 & 2034

Figure 57: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By End User, 2025

Figure 58: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Country/Sub-region, 2025 & 2034

Figure 59: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Country/Sub-region, 2025

Figure 60: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Technique, 2025 & 2034

Figure 61: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Technique, 2025

Figure 62: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Disease Type, 2025 & 2034

Figure 63: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Disease Type, 2025

Figure 64: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By End User, 2025 & 2034

Figure 65: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By End User, 2025

Figure 66: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Value (USD billion), By Country/Sub-region, 2025 & 2034

Figure 67: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Value Share (%), By Country/Sub-region, 2025

Figure 68: Global Infectious Disease Point-of-care (POC) Diagnostics Market Share, By Company, 2025

Table 01: Global Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Technique, 2021-2034

Table 02: Global Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034

Table 03: Global Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By End User, 2021-2034

Table 04: Global Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, by Region, 2021-2034

Table 05: North America Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Technique, 2021-2034

Table 06: North America Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034

Table 07: North America Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By End User, 2021-2034

Table 08: North America Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Country, 2021-2034

Table 09: Europe Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Technique, 2021-2034

Table 10: Europe Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034

8able 11: Europe Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By End User, 2021-2034

Table 12: Europe Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Country/Sub-region, 2021-2034

Table 13: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Technique, 2021-2034

Table 14: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034

Table 15: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By End User, 2021-2034

Table 16: Asia Pacific Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Country/Sub-region, 2021-2034

Table 17: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Technique, 2021-2034

Table 18: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034

Table 19: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By End User, 2021-2034

Table 20: Latin America Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Country/Sub-region, 2021-2034

Table 21: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Technique, 2021-2034

Table 22: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034

Table 23: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By End User, 2021-2034

Table 24: Middle East & Africa Infectious Disease Point of Care (POC) Diagnostics Market Revenue (USD billion) Forecast, By Country/Sub-region, 2021-2034

  • 2021-2034
  • 2025
  • 2021-2024
  • 180
Download Free Sample

    man icon
    Mail icon

Get 20% Free Customization

Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.

Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann